-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Stephen Hahn
-
New FDA Commissioner Confirmed
Posted: February 12, 2020 December 12, 2019—Stephen M. Hahn, MD, FASTRO, was confirmed as commissioner of the U.S. Food and Drug Administration by a Senate vote of 72 to 18. Dr. Hahn will vacate his current position as chief executive officer of The University of Texas MD Anderson Cancer Center, which he has held since…
-
Stephen M. Hahn, MD, FASTRO
Posted: December 11, 2019 Stephen M. Hahn, MD, FASTRO, has been nominated to be the next commissioner of the U.S. Food and Drug Administration by President Trump. If approved by the Senate, Dr. Hahn will vacate his position as chief executive officer of The University of Texas MD Anderson Cancer Center, which he has held…